Charles Earl Drake

US Patent:

8551481, Oct 8, 2013

Filed:

Oct 22, 2009

Appl. No.:

12/578887

Inventors:

Drew M Pardoll - Brookeville MD, US
Ching-Tai Huang - Taipei, TW
Jonathan Powell - Baltimore MD, US
Charles Drake - Baltimore MD, US
Dario A Vignali - Germantown TN, US
Creg J Workman - Memphis TN, US

Assignee:

The Johns Hopkins University - Baltimore MD
St. Jude Children's Research Hospital, Inc. - Memphis TN

International Classification:

A61K 39/00
A61K 39/395
A61K 39/38
C12P 21/08

US Classification:

4241391, 4241411, 4241841, 5303881, 53038875

Abstract:

Regulatory T cells (Treg) limit autoimmunity but can also attenuate the magnitude of anti-pathogen and anti-tumor immunity. Understanding the mechanism of Treg function and therapeutic manipulation of Treg in vivo requires identification of Treg selective receptors. A comparative analysis of gene expression arrays from antigen specific CD4+ T cells differentiating to either an effector/memory or a regulatory phenotype revealed Treg selective expression of LAG-3 (CD223), a CD4-related molecule that binds MHC class II. LAG-3 expression on CD4+ T cells correlates with the cells' in vitro suppressor activity, and ectopic expression of LAG-3 on CD4 T cells confers suppressor activity on the T cells. Antibodies to LAG-3 inhibit suppression both in vitro and in vivo. LAG-3 marks regulatory T cell populations and contributes to their suppressor activity.

US Patent:

20060240024, Oct 26, 2006

Filed:

Mar 1, 2004

Appl. No.:

10/547371

Inventors:

Drew Pardoll - Brookeville MD, US
Ching-Tai Huang - Taipei, TW
Dario Vignali - Bartlett TN, US
Creg Workman - Memphis TN, US
Jonathan Powell - Baltimore MD, US
Charles Drake - Baltimore MD, US

Assignee:

The Johns Hopkins University - Baltimore MD
St Jude Children's Research Hospital Inc. - Memphis TN

International Classification:

A61K 39/395

US Classification:

424155100

Abstract:

Regulatory T cells (Treg) limit autoimmunity but can also attenuate the magnitude of anti-pathogen and anti-tumor immunity. Understanding the mechanism of Treg function and therapeutic manipulation of Treg in vivo requires identification of Treg selective receptors. A comparative analysis of gene expression arrays from antigen specific CD4+ T cells differentiating to either an effector/memory or a regulatory phenotype revealed Treg selective expression of LAG-3 (CD223), a CD4-related molecule that binds MHC class II. LAG-3 expression on CD4+ T cells correlates with the cells' in vitro suppressor activity, and ectopic expression of LAG-3 on CD4 T cells confers suppressor activity on the T cells. Antibodies to LAG-3 inhibit suppression both in vitro and in vivo. LAG-3 marks regulatory T cell populations and contributes to their suppressor activity.

US Patent:

20130177625, Jul 11, 2013

Filed:

Oct 29, 2012

Appl. No.:

13/663045

Inventors:

Young Jun Kim - Yongin, KR
Drew M. Pardoll - Brookeville MD, US
Charles George Drake - Baltimore MD, US
Meghan Davis - Baltimore MD, US
Juan Fu - Baltimore MD, US

Assignee:

The Johns Hopkins University - Baltimore MD

International Classification:

A61K 39/00
A61K 45/06
A61K 35/12

US Classification:

424450, 4242781, 424 851, 4242831, 4241841, 4242771

Abstract:

The invention provides provides immunogenic compositions comprising neoplastic cells expressing a cytokine (GM-CSF) formulated with at least one TLR agonist and methods of using the composition to induce or enhance an immune response.

US Patent:

20190240327, Aug 8, 2019

Filed:

Nov 8, 2013

Appl. No.:

14/075566

Inventors:

- BALTIMORE MD, US
Drew M. Pardoll - Brookeville MD, US
Xiaoyu Pan - Cockeysville MD, US
Charles G. Drake - Baltimore MD, US
Jonathan D. Powell - Baltimore MD, US
Ching-Tai Huang - Taipei, TW
Joseph Barbi - East Amherst NY, US
Fan Pan - Baltimore MD, US

International Classification:

A61K 39/395
A61K 35/14
A61K 31/713
A61K 39/00

Abstract:

We demonstrate herein that neuritin controls the homeostasis of regulatory T cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory T cells in various disease settings is described. Thus manipulation of Treg cells and DCs through neuritin can be used to enhance immunotherapy of autoimmune diseases, cancer and infectious diseases, as well as enhance lymphocyte engraftment in settings of donor lymphocyte infusion, bone marrow transplant, as well as other types of transplants, and adoptive transfer.

US Patent:

20160193313, Jul 7, 2016

Filed:

Dec 17, 2015

Appl. No.:

14/972865

Inventors:

- Baltimore MD, US
Drew M. Pardoll - Brookeville MD, US
Charles George Drake - Baltimore MD, US
Meghan Davis - Baltimore MD, US
Juan Fu - Baltimore MD, US

International Classification:

A61K 39/00
A61K 38/19
A61K 31/739
A61K 45/06

Abstract:

The invention provides immunogenic compositions comprising neoplastic cells expressing a cytokine (GM-CSF) formulated with at least one TLR agonist and methods of using the composition to induce or enhance an immune response.

US Patent:

20140155678, Jun 5, 2014

Filed:

Jun 19, 2012

Appl. No.:

14/127597

Inventors:

Jing Zeng - Rockville MD, US
Charles George Drake - Baltimore MD, US
Drew M. Pardoll - Brookeville MD, US
Michael Lim - Reisterstown MD, US

International Classification:

A61N 5/10
A61K 45/06
A61K 39/395

US Classification:

600 1, 604 20

Abstract:

An approach combining immune-based therapies with focused radiation, including stereotactic radiation, to treat cancers is disclosed. The use of focused radiation primes the immune system in a similar manner to vaccines to augment immune-based therapies and can counteract the suppressive effects of a tumor. The combination of focused radiation and immune-based therapies, including administration of at least one immunotherapeutic agent, improves survival compared to each therapy alone and can, in some cases, lead to a durable cure. Accordingly, focused radiation can be an adjuvant for immune-based therapies for treating cancers.